[1] 郏博,吕超,常建华,等. 非小细胞肺癌非常见突变靶向治疗研究进展[J]. 中华医学杂志,2022,102(13):969-976. DOI:10.3760/cma.j.cn112137-20211008-02215.
[2] Takeuchi K. Discovery stories of RET fusions in lung cancer: a mini-review [J]. Front Physiol, 2019, 10: 216. DOI: 10.3389/fphys.2019.00216.
[3] 马千里,张瑾,鲍彤,等. RET融合肺癌的特征及诊疗进展[J]. 中华胸心血管外科杂志,2022,38(5):305-309. DOI:10.3760/cma.j.cn112434-20210219-00062.
[4] Kato S, Subbiah V, Marchlik E, et al. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients [J]. Clin Cancer Res, 2017, 23(8):1988-1997. DOI: 10.1158/1078-0432.CCR-16-1679.
[5] Lee J, Ku BM, Shim JH, et al. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice[J]. Jpn J Clin Oncol, 2020, 50(5): 594-601. DOI: 10.1093/jjco/hyaa019.
[6] Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors [J].Cancer Discov, 2015, 5(8): 850-859. DOI: 10.1158/2159-8290.CD-15-0285.
[7] Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients[J]. J Clin Oncol, 2009, 27(10): 1667-1674. DOI: 10.1200/JCO.2008.19.1635.
[8] Baldacci S, Kherrouche Z, Cockenpot V. MET amplification increases the metastatic spread of EGFR-mutated NSCLC [J]. Lung Cancer, 2018, 125:57-67. DOI: 10.1016/j.lungcan.2018.09.008.
[9] 吴丹,李静,姚梅宏,等.非小细胞肺癌表皮生长因子受体、间变性淋巴瘤激酶、ROS1基因突变及突变共存的临床病理学意义[J].中华病理学杂志,2021,50(3): 251-253. DOI: 10.3760/cma.j.cn112151-20200617-00482.
|